Cognitive health and gut health have long been considered separate domains, but a growing body of evidence is forcing a rethink. For the estimated 10 million people living with inflammatory bowel disease worldwide, the implications extend well beyond gastrointestinal symptoms — emerging data suggest that chronic intestinal inflammation may be quietly reshaping brain function over time.
This PRISMA-compliant systematic review, published in the Journal of Crohn's & Colitis, synthesized findings from 66 studies examining the IBD–cognition relationship: 31 population-level studies, 13 genetic investigations including Mendelian randomization and genome-wide association studies, and 22 preclinical models. The review assessed multiple cognitive domains — memory, attention, and executive function — and specifically interrogated whether IBD treatments might modulate cognitive trajectories. Proposed mechanistic pathways include chronic low-grade systemic inflammation, disruption of gut-brain axis signaling, nutritional deficiencies common in IBD, and psychological comorbidities such as anxiety and depression, which are themselves independent risk factors for dementia.
What makes this review particularly valuable is its scope across biological levels of evidence, from animal models to human epidemiology to causal genetic inference. Mendelian randomization studies, which exploit genetic variants as natural experiments to test causal relationships, lend more weight to a directional IBD-to-cognition pathway than observational data alone could provide. That said, the review's authors acknowledge that results across studies remain heterogeneous — a pattern that likely reflects differences in disease phenotype, duration, treatment regimens, and cognitive assessment tools. The potential role of biologics and immunomodulatory therapies in either attenuating or exacerbating cognitive risk is a clinically underexplored angle that this review highlights. Overall, this is a confirmatory and synthesizing contribution rather than a paradigm shift, but it substantially elevates the clinical urgency of monitoring cognitive function in IBD patients, particularly those with longstanding, poorly controlled disease.